Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38361
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qi Q. | en |
dc.contributor.author | Chao Y. | en |
dc.contributor.author | Hill A. | en |
dc.contributor.author | Kang J. | en |
dc.contributor.author | Wang L. | en |
dc.contributor.author | Li K. | en |
dc.contributor.author | Gan H. | en |
dc.contributor.author | Wu Z. | en |
dc.contributor.author | Yen C.-J. | en |
dc.contributor.author | Markman B. | en |
dc.date.accessioned | 2021-05-14T13:05:07Z | en |
dc.date.available | 2021-05-14T13:05:07Z | en |
dc.date.copyright | 2017 | en |
dc.date.created | 20200303 | en |
dc.date.issued | 2020-03-03 | en |
dc.identifier.citation | Annals of Oncology. 28 (Supplement 3) (pp iii54), 2017. Date of Publication: June 2017. | en |
dc.identifier.issn | 0923-7534 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/38361 | en |
dc.language | en | en |
dc.publisher | Elsevier Ltd | en |
dc.relation.ispartof | Annals of Oncology | en |
dc.subject.mesh | response evaluation criteria in solid tumors | - |
dc.subject.mesh | upper respiratory tract infection | - |
dc.subject.mesh | sorafenib | - |
dc.subject.mesh | sorafenib/ct | - |
dc.subject.mesh | tislelizumab | - |
dc.subject.mesh | tislelizumab/ct | - |
dc.subject.mesh | advanced cancer | - |
dc.subject.mesh | antineoplastic activity | - |
dc.subject.mesh | ascites | - |
dc.subject.mesh | cancer control | - |
dc.subject.mesh | coughing | - |
dc.subject.mesh | decreased appetite | - |
dc.subject.mesh | drug dose escalation | - |
dc.subject.mesh | drug eruption | - |
dc.subject.mesh | drug fatality | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | drug tolerability | - |
dc.subject.mesh | fatigue | - |
dc.subject.mesh | fever | - |
dc.subject.mesh | liver cell carcinoma | - |
dc.subject.mesh | phase 1 | - |
dc.title | Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). | en |
dc.type | Article | en |
dc.type.studyortrial | Clinical trial | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/annonc/mdx261.139 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 32135938 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32135938] | en |
dc.identifier.source | 2005032559 | en |
dc.identifier.institution | (Yen) National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China) (Markman) Monash Medical Centre, Clayton, Australia (Chao) Taipei Veterens General Hospital, Taipei City, Taiwan (Republic of China) (Hill) Tasman Oncology Research Ltd., Southport, Australia (Kang, Wang, Li, Qi) BeiGene (Beijing) Co. Ltd., Beijing, China (Wu) BeiGene USA Inc., Fort Lee, New Jersey, United States (Gan) Austin Hospital, Melbourne, Australia | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.